ABSTRACT:
Atopic dermatitis (AD) is an inflammatory condition characterized by T helper 2 (Th2) immunological responses and loss of epidermal barrier function. Chronic inflammatory dermatosis called atopic dermatitis (AD) can flare up and go into remission at different times. Intense, ongoing itching, as well as the severity and variety of clinical symptoms, are characteristics of AD. The methods of delivering topical medications, commonly employed for addressing various skin conditions, have evolved significantly from their primitive forms. Progress in percutaneous absorption, the refinement of product designs driven by a deeper comprehension of how drugs, formulations, and skin interact, along with associated research endeavors, and the implementation of quality-centric design principles have collectively propelled their advancement. Topical drug delivery entails drug transportation from a skin-based product to a local target location, followed by drug clearance by diffusion, metabolism, and excretion. and the deeper tissues and the remainder of the body's dermal circulation.
Cite this article:
Swati Raysing, Vaibhav Mote. Emerging Strategies in Innovative Topical Delivery Systems for Treating Atopic Dermatitis. Asian Journal of Pharmaceutical Research. 2025; 15(2):215-2. doi: 10.52711/2231-5691.2025.00035
Cite(Electronic):
Swati Raysing, Vaibhav Mote. Emerging Strategies in Innovative Topical Delivery Systems for Treating Atopic Dermatitis. Asian Journal of Pharmaceutical Research. 2025; 15(2):215-2. doi: 10.52711/2231-5691.2025.00035 Available on: https://asianjpr.com/AbstractView.aspx?PID=2025-15-2-20
REFERENCES:
1. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018; 4(1).
2. Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin. 2010; 26(3):633–40.
3. Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, LeBovidge J, et al. Atopic dermatitis: A practice parameter update 2012. Journal of Allergy and Clinical Immunology. 2013; 131(2):295-299.e27.
4. Date AA, Naik B, Nagarsenker MS. Novel Drug Delivery Systems: Potential in Improving Topical Delivery of Antiacne Agents. Skin Pharmacol Physiol. 2006; 19(1):2–16.
5. Katz MA, Cheng CH, Nacht S. Methods and compositions for topical delivery of benzoyl peroxide. US Patent No. 5,879,716. 1999.
6. Ting WW, Vest CD, Sontheimer RD. Review of traditional and novel modalities that enhance the permeability of local therapeutics across the stratum corneum. Int J Dermatol. 2004; 43(7):538–47.
7. Leung D. New concepts in the pathogenesis of atopic dermatitis. Curr Opin Immunol 2003; 15(6):634–8.
8. Boguniewicz M, Leung DYM. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011; 242(1): 233–46.
9. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanisms. Journal of Allergy and Clinical Immunology. 2008; 121(6):1337–43.
10. Garnacho-Saucedo G, Salido-Vallejo R, Moreno-Giménez JC. Actualización en dermatitis atópica. Propuesta de algoritmo de actuación. Actas Dermosifiliogr. 2013; 104(1):4–16.
11. Sharma N, Agarwal G, Rana AC, Ali Bhat Z, Kumar D, Bhat A. Transdermal Drug Delivery System: A Tool For Novel Drug Delivery System [Internet]. Available from: http://www.ijddr.in
12. Saeki H, Furue M, Furukawa F, Hide M, Ohtsuki M, Katayama I, et al. Guidelines for management of atopic dermatitis. J Dermatol. 2009; 36(10):563–77.
13. Nola I, Kostović K, Kotrulja L, Lugović L. The use of emollients as sophisticated therapy in dermatology. Acta Dermatovenerol Croat. 2003; 11(2):80–7.
14. Lod??n M. Role of Topical Emollients and Moisturizers in the Treatment of Dry Skin Barrier Disorders. Am J Clin Dermatol. 2003; 4(11):771–88.
15. Tamarkin D, Friedman D, Shemer A. Emollient foam in topical drug delivery. Expert Opin Drug Deliv. 2006; 3(6):799–807.
16. Eichenfield LF, Krakowski AC, Piggott C, Del Rosso J, Baldwin H, Friedlander SF, et al. Evidence-Based Recommendations for the Diagnosis and Treatment of Pediatric Acne. Pediatrics. 2013; 131(Supplement_3):S163–86.
17. Kim BS, Sun K, Papp K, Venturanza M, Nasir A, Kuligowski ME. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol. 2020; 82(6):1305–13.
18. Fahrbach K, Tarpey J, Washington EB, Hughes R, Thom H, Neary MP, et al. Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis. Dermatol Ther (Heidelb). 2020; 10(4):681–94.
19. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014; 71(1):116–32.
20. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Patient burden and quality of life in atopic dermatitis in US adults. Annals of Allergy, Asthma & Immunology 2018; 121(3):340–7.
21. Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. Journal of Allergy and Clinical Immunology. 2020; 145(2):572–82.
22. Ahluwalia J, Udkoff J, Waldman A, Borok J, Eichenfield LF. Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook. Drugs. 2017; 77(13):1389–97.
23. Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016; 75(3):494-503.e6.
24. Ahmed A, Solman L, Williams HC. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal. British Journal of Dermatology. 2018; 178(3):659–62.
25. Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflammation Research. 2015; 64(1):41–51.
26. Tanimoto A, Shinozaki Y, Yamamoto Y, Katsuda Y, Taniai‐Riya E, Toyoda K, et al. A novel <scp>JAK</scp> inhibitor <scp>JTE</scp> ‐052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents. Exp Dermatol. 2018; 27(1):22–9.
27. Amano W, Nakajima S, Kunugi H, Numata Y, Kitoh A, Egawa G, et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. Journal of Allergy and Clinical Immunology. 2015; 136(3):667-677.e7.
28. Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs. 2007; 8(5):364–72.
29. Baumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly Selective Phosphodiesterase 4 Inhibitors for the Treatment of Allergic Skin Diseases and Psoriasis. Inflammation & Allergy-Drug Targets. 2007; 6(1):17–26.
30. Yamamura K, Nakahara T. The Dawn of a New Era in Atopic Dermatitis Treatment. J Clin Med. 2022; 11(20):6145.
31. Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson WR, Kirby DS, et al. Type 4 Phosphodiesterase Inhibitors Have Clinical and In Vitro Anti-inflammatory Effects in Atopic Dermatitis. Journal of Investigative Dermatology. 1996; 107(1):51–6.
32. Jimenez JL, Punzón C, Navarro J, Muñoz-Fernández MA, Fresno M. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther. 2001; 299(2):753–9.
33. Yamamoto Y, Otsuka A, Nakashima C, Ishida Y, Honda T, Egawa G, et al. Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model. J Dermatol Sci. 2020; 97(2):161–4.
34. Fridman JS, Scherle PA, Collins R, Burn T, Neilan CL, Hertel D, et al. Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation. Journal of Investigative Dermatology. 2011; 131(9):1838–44.
35. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010; 115(15):3109–17.
36. Stuetz A, Baumann K, Grassberger M, Wolff K, Meingassner JG. Discovery of Topical Calcineurin Inhibitors and Pharmacological Profile of Pimecrolimus. Int Arch Allergy Immunol. 2006; 141(3):199–212.
37. Carr WW. Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations. Pediatric Drugs. 2013; 15(4):303–10.
38. Lin AN. Innovative Use of Topical Calcineurin Inhibitors. Dermatol Clin. 2010; 28(3):535–45.
39. FDA, CDER. Prograf (tacrolimus) capsules/injection label [Internet]. Available from: www.fda.gov/medwatch
40. Lalan M, Baweja J, Misra A. Atopic Dermatitis: Drug Delivery Approaches in Disease Management. Crit Rev Ther Drug Carrier Syst. 2015; 32(4):323–61.
41. Abramovits W. A clinician’s paradigm in the treatment of atopic dermatitis. J Am Acad Dermatol. 2005; 53(1):S70–7.
42. Hughes J, Rustin M. Corticosteroids. Clin Dermatol. 1997; 15(5):715–21.
43. Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol. 2005; 53(1):S17–25.
44. Schfer-Korting M, Korting HC, Ponce-Pschl E. Liposomal tretinoin for uncomplicated acne vulgaris. Clin Investig. 1994; 72(12):1086–91.
45. Brisaert M, Gabriëls M, Matthijs V, Plaizier-Vercammen J. Liposomes with tretinoin: a physical and chemical evaluation. J Pharm Biomed Anal. 2001; 26(5–6):909–17.
46. Heuschkel S, Goebel A, Neubert RHH. Microemulsions—Modern Colloidal Carrier for Dermal and Transdermal Drug Delivery. J Pharm Sci. 2008; 97(2):603–31.
47. Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interface Sci. 2006; 123–126:369–85.
48. Gloor M, Haus G, Keipert S. Keratolytic Activity of Microemulsions. Skin Pharmacol Physiol. 2003; 16(3):151–5.
49. Changez M, Varshney M, Chander J, Dinda AK. Effect of the composition of lecithin/n-propanol/isopropyl myristate/water microemulsions on barrier properties of mice skin for transdermal permeation of tetracaine hydrochloride: In vitro. Colloids Surf B Biointerfaces. 2006; 50(1):18–25.
50. Kemken J, Ziegler A, Müller BW. Influence of supersaturation on the pharmacodynamic effect of bupranolol after dermal administration using microemulsions as vehicle. Pharm Res. 1992 Apr; 9(4):554-8.
51. Peltola S, Saarinen-Savolainen P, Kiesvaara J, Suhonen TM, Urtti A. Microemulsions for topical delivery of estradiol. Int J Pharm. 2003; 254(2):99–107.
52. Biju SS, Ahuja A, Khar RK. Tea Tree Oil Concentration in Follicular Casts After Topical Delivery: Determination by High-Performance Thin Layer Chromatography Using a Perfused Bovine Udder Model. J Pharm Sci. 2005; 94(2):240–5.
53. Yilmaz E, Borchert HH. Effect of lipid-containing, positively charged nanoemulsions on skin hydration, elasticity and erythema—An in vivo study. Int J Pharm. 2006; 307(2):232–8.
54. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002; 54:S131–55.
55. Lucks JS, Müller RH, inventors; Medac Klinische Spezialpraep, assignee. Medication vehicles made of solid lipid particles (solid lipid Nanospheres SLN). European Patent EP. 0605497; 1996.
56. Wissing S, Lippacher A, Müller R. Investigations on the occlusive properties of solid lipid nanoparticles (SLN). J Cosmet Sci. 2001; 52(5):313–24.
57. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes — novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. Journal of Controlled Release. 2000; 65(3):403–18.
58. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes — novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. Journal of Controlled Release. 2000; 65(3):403–18.
59. Touitou E, Godin B, Dayan N, Weiss C, Piliponsky A, Levi-Schaffer F. Intracellular delivery mediated by an ethosomal carrier. Biomaterials. 2001; 22(22):3053–9.
60. Li G, Fan Y, Fan C, Li X, Wang X, Li M, et al. Tacrolimus-loaded ethosomes: Physicochemical characterization and in vivo evaluation. European Journal of Pharmaceutics and Biopharmaceutics. 2012; 82(1):49–57.
61. Hebert AA, Cook-Bolden FE, Basu S, Calvarese B, Trancik RJ, Desonide Hydrogel Study Group. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. J Drugs Dermatol 2007; 6(2):175–81.
62. Kerney DL, Ford RO, Gotz V. Self-reported participant experience with desonide hydrogel in the treatment of mild to moderate atopic dermatitis. Cutis. 2011; 88(1 Suppl):18–24.
63. Ladenheim D, Martin GP, Marriott C, Hollingsbee DA, Brown MB. An In-vitro Study of the Effect of Hydrocolloid Patch Occlusion on the Penetration of Triamcinolone Acetonide through Skin in Man. Journal of Pharmacy and Pharmacology. 2011; 48(8):806–11.
64. Dibyajyoti Saha, Ankit Tamrakar, Mayukh Jana, Supradip Mandal. Skin Cancer: Dance of Death. Asian J. Pharm. Res. 1(2): April-June 2011; Page 34-36.
65. Design, Formulation and in vitro Drug Release from Transdermal Patches containing Nebivolol Hydrochloride as Model Drug. Asian J. Pharm. Res. 2012; 2(4): 136-141.
66. S. More, T. Ghadge, S. Dhole. Microneedle: an Advanced Technique in Transdermal Drug Delivery System. Asian J. Res. Pharm. Sci. 2013; 3(3); 141-148.
67. N. Krishna Veni, P. Yashwanthi, B. Hemalatha, K. Padmalatha. A Review on Emulgels as a Novel Approach for Topical Drug Delivery. Asian Journal of Research in Pharmaceutical Sciences. 2022; 12(2):163-8.
68. Abhishek, Akshit Katnauria, Happy, Kapil Kumar Verma. A Review Article on Transdermal Drug Delivery System. Asian Journal of Pharmacy and Technology. 2024; 14(2):173-8.
69. Vaseeha Banu T.S., Sandhya K.V., K.N. Jayaveera. Approaches and Current Trends of Transdermal Drug Delivery System- A Review. Research J. Pharma. Dosage Forms and Tech. 2013; 5(4): 177-190.
70. Bhakti R. Chorghe, Swapnil T. Deshpande, Rohit D. Shah, Swati S. Korabu, Sagar V. Motarwar. Transdermal Drug Delivery System: A Review. Research J. Pharma. Dosage Forms and Tech. 2013; 5(2): 65-69.
71. Saloni Bhandari. Ethosomes: A Novel Vesicular Innovation to Enhance Transdermal Delivery of Drugs. Research Journal of Pharmaceutical Dosage Forms and Technology.2022; 14(1):72-8.
72. Rakesh K Sindhu, Mansi Chitkara, Gagandeep Kaur, Preeti Jaiswal, Ashutosh Kalra, Inderbir Singh, Pornsak Sriamornsak. Skin Penetration Enhancer’s in Transdermal Drug Delivery Systems. Research J. Pharm. and Tech. 2017; 10(6): 1809-1815.
73. Monisha C, GNK. Ganesh, Mythili L, Kayalvizhi Radhakrishnan. A Review on Ethosomes for Transdermal Application. Research J. Pharm. and Tech. 2019; 12(7): 3133-3143.